-DOCSTART- -X- O
Pseudoviruses -X- _ O
are -X- _ O
useful -X- _ O
virological -X- _ O
tools -X- _ O
because -X- _ O
of -X- _ O
their -X- _ O
safety -X- _ O
and -X- _ O
versatility -X- _ O
; -X- _ O
however -X- _ O
the -X- _ O
low -X- _ O
titer -X- _ O
of -X- _ O
these -X- _ O
viruses -X- _ O
substantially -X- _ O
limits -X- _ O
their -X- _ O
wider -X- _ O
applications. -X- _ O
We -X- _ O
developed -X- _ O
a -X- _ O
highly -X- _ O
efficient -X- _ O
pseudovirus -X- _ O
production -X- _ O
system -X- _ O
capable -X- _ O
of -X- _ O
yielding -X- _ O
100 -X- _ O
times -X- _ O
more -X- _ O
rabies -X- _ O
pseudovirus -X- _ O
than -X- _ O
the -X- _ O
traditional -X- _ O
method. -X- _ O
Employing -X- _ O
the -X- _ O
high-titer -X- _ O
pseudoviruses -X- _ O
, -X- _ O
we -X- _ O
have -X- _ O
developed -X- _ O
robust -X- _ O
in -X- _ O
vitro -X- _ O
and -X- _ O
in -X- _ O
vivo -X- _ O
neutralization -X- _ O
assays -X- _ O
for -X- _ O
the -X- _ O
evaluation -X- _ O
of -X- _ O
rabies -X- _ O
vaccine -X- _ O
, -X- _ O
which -X- _ O
traditionally -X- _ O
relies -X- _ O
on -X- _ O
live-virus -X- _ O
based -X- _ O
assays. -X- _ O
Compared -X- _ O
with -X- _ O
current -X- _ O
rapid -X- _ B-Comparison
fluorescent -X- _ I-Comparison
focus -X- _ I-Comparison
inhibition -X- _ I-Comparison
test -X- _ I-Comparison
( -X- _ I-Comparison
RFFIT -X- _ I-Comparison
) -X- _ I-Comparison
, -X- _ O
our -X- _ O
in -X- _ B-Intervention
vitro -X- _ I-Intervention
pseudovirus-based -X- _ I-Intervention
neutralization -X- _ I-Intervention
assay -X- _ I-Intervention
( -X- _ I-Intervention
PBNA -X- _ I-Intervention
) -X- _ I-Intervention
is -X- _ O
much -X- _ B-Outcome
less -X- _ I-Outcome
labor-intensive -X- _ I-Outcome
while -X- _ I-Outcome
demonstrating -X- _ I-Outcome
better -X- _ I-Outcome
reproducibility. -X- _ I-Outcome
Moreover -X- _ O
, -X- _ O
the -X- _ O
in -X- _ B-Intervention
vivo -X- _ I-Intervention
PBNA -X- _ I-Intervention
assay -X- _ O
was -X- _ O
also -X- _ O
found -X- _ O
to -X- _ O
be -X- _ O
superior -X- _ B-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
live -X- _ I-Outcome
virus -X- _ I-Outcome
based -X- _ I-Outcome
assay. -X- _ I-Outcome
Following -X- _ O
intravenous -X- _ O
administration -X- _ O
, -X- _ O
the -X- _ O
pseudovirus -X- _ O
effectively -X- _ O
infected -X- _ O
the -X- _ O
mice -X- _ B-Patient
, -X- _ O
with -X- _ O
dynamic -X- _ O
viral -X- _ O
distributions -X- _ O
being -X- _ O
sequentially -X- _ O
observed -X- _ O
in -X- _ O
spleen -X- _ O
, -X- _ O
liver -X- _ O
and -X- _ O
brain. -X- _ O
Furthermore -X- _ O
, -X- _ O
data -X- _ O
from -X- _ O
in -X- _ B-Intervention
vivo -X- _ I-Intervention
PBNA -X- _ I-Intervention
showed -X- _ O
great -X- _ O
agreement -X- _ O
with -X- _ O
those -X- _ O
generated -X- _ O
from -X- _ O
the -X- _ O
live -X- _ O
virus -X- _ O
model -X- _ O
but -X- _ O
with -X- _ O
the -X- _ O
experimental -X- _ B-Outcome
time -X- _ I-Outcome
significantly -X- _ I-Outcome
reduced -X- _ I-Outcome
from -X- _ I-Outcome
2 -X- _ I-Outcome
weeks -X- _ I-Outcome
to -X- _ I-Outcome
3 -X- _ I-Outcome
days. -X- _ I-Outcome
Taken -X- _ O
together -X- _ O
, -X- _ O
the -X- _ O
effective -X- _ O
pseudovirus -X- _ O
production -X- _ O
system -X- _ O
facilitated -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
novel -X- _ O
PBNA -X- _ O
assays -X- _ O
which -X- _ O
could -X- _ O
replace -X- _ O
live -X- _ B-Comparison
virus-based -X- _ I-Comparison
traditional -X- _ I-Comparison
assays -X- _ I-Comparison
due -X- _ O
to -X- _ O
its -X- _ O
safety -X- _ O
, -X- _ O
rapidity -X- _ O
, -X- _ O
reproducibility -X- _ O
and -X- _ O
high -X- _ O
throughput -X- _ O
capacity -X- _ O
. -X- _ O

